Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinhuang Diwan is a traditional Chinese medicine (TCM) formulation developed by Zhejiang Weikang Pharmaceutical. It is a specific dosage form (dropping pills) of the Yinhuang formula, which is primarily composed of extracts from *Lonicera japonica* (honeysuckle) and *Scutellaria baicalensis* (baical skullcap). The active constituents are standardized to chlorogenic acid and baicalin. Yinhuang Diwan is indicated for the treatment of recurrent aphthous ulcers (RAU), as well as acute pharyngitis, tonsillitis, and upper respiratory tract infections. Its mechanism of action involves anti-inflammatory, antibacterial, and antiviral properties, effectively clearing heat and detoxifying according to TCM principles. The dropping pill formulation is designed for rapid dissolution and absorption, providing quick relief for oral and throat conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yinhuang diwan.